U.S. License Holder:
Date of License:
BLINCYTO (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with:
B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent;
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).